Anne Wojcicki
Latest
23andMe lays off 100 workers amid shrinking demand for DNA tests
If you're skittish about DNA testing services, you're not the only one -- and it's directly affecting one of the heavyweights in the field. The 23andMe team is laying off about 100 workers, or 14 percent of its total workforce, in light of declining sales. The job cuts will focus on units responsible for growing and scaling the company. In the months ahead, 23andMe expects to cut back its work on clinical studies and focus more on its home testing and therapeutic offerings.
23andMe's Anne Wojcicki envisions the future of preventative medicine
Anne Wojcicki and her genetic sequencing company 23andMe are locked in a battle with the FDA. Even though it can't report results to customers right now, Wojcicki isn't letting herself get bogged down in the present. At SXSW 2014 she laid out her vision of the future of preventative medicine -- one where affordable genome sequencing comes together with "big data." In addition to simply harvesting your genetic code, the company is doing research into how particular genes effect your susceptibility to disease or your reaction to treatments. And 23andMe isn't keeping this information locked down. It has been building APIs that allow it to share the results of its research as well as the results your genetic tests, should you wish to.
